NASDAQ:CYCCP Cyclacel Pharmaceuticals (CYCCP) Stock Price, News & Analysis → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Free CYCCP Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$18.79▼$18.7950-Day Range$5.00▼$6.0352-Week Range$4.25▼$8.07Volume202 shsAverage Volume604 shsMarket CapitalizationN/AP/E RatioN/ADividend Yield3.19%Price TargetN/A Stock AnalysisStock AnalysisCompetitorsDividendHeadlinesSocial MediaStock AnalysisCompetitorsDividendHeadlinesSocial Media Get Cyclacel Pharmaceuticals alerts: Email Address Ad Gold Safe ExchangeTrump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… About Cyclacel Pharmaceuticals Stock (NASDAQ:CYCCP)Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase I clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase I clinical trial for the treatment of advanced leukemias. Its oncology development programs also comprise Sapacitabine, an orally available prodrug of CNDAC, which is a novel nucleoside analog. In addition, the company's oncology development programs include seliciclib, a CDK inhibitor. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.Read More Ad Gold Safe ExchangeTrump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… CYCCP Stock News HeadlinesMarch 19, 2024 | globenewswire.comCyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateMarch 13, 2024 | globenewswire.comCyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial ResultsMarch 28, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.March 7, 2024 | globenewswire.comCyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024March 6, 2024 | globenewswire.comCyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax CreditFebruary 20, 2024 | finance.yahoo.comCyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor ConferenceFebruary 20, 2024 | globenewswire.comCyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor ConferenceJanuary 19, 2024 | msn.comCyclacel Pharmaceuticals files to sell 411K shares of common stockMarch 28, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.January 9, 2024 | investorplace.comWhy Is Cyclacel Pharmaceuticals (CYCC) Stock Down 9% Today?December 22, 2023 | msn.comCyclacel Pharmaceuticals announces registered direct and private placement offeringDecember 18, 2023 | finance.yahoo.comCyclacel Pharmaceuticals Reports Fadraciclib Phase 1 Data Suggesting Efficacy Against Tumors With CDKN2A, CDKN2B and MTAP DeletionsNovember 30, 2023 | finance.yahoo.comCyclacel Regains Compliance With Nasdaq Listing Rule Following Filing of Its Form 10-Q With the SECNovember 14, 2023 | msn.comCyclacel Pharmaceuticals GAAP EPS of -$0.49 misses by $0.13November 14, 2023 | finance.yahoo.comCyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q3 2023 Earnings Call TranscriptNovember 13, 2023 | finance.yahoo.comCyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business UpdateNovember 7, 2023 | finance.yahoo.comCyclacel Pharmaceuticals to Release Third Quarter 2023 Financial ResultsAugust 19, 2023 | finance.yahoo.comCYCC Aug 2023 2.500 callAugust 10, 2023 | finance.yahoo.comQ2 2023 Cyclacel Pharmaceuticals Inc Earnings CallMay 16, 2023 | finance.yahoo.comCyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q1 2023 Earnings Call TranscriptMay 12, 2023 | finance.yahoo.comQ1 2023 Cyclacel Pharmaceuticals Inc Earnings CallMay 11, 2023 | msn.comRecap: Cyclacel Pharmaceuticals Q1 EarningsMay 11, 2023 | msn.comCyclacel Pharmaceuticals GAAP EPS of -$0.47 beats by $0.19May 11, 2023 | finance.yahoo.comCyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business UpdateMay 5, 2023 | seekingalpha.comCyclacel Pharmaceuticals receives $4.7M R&D tax creditMay 4, 2023 | finance.yahoo.comCyclacel Pharmaceuticals to Release First Quarter 2023 Financial ResultsMarch 7, 2023 | finance.yahoo.comQ4 2022 Cyclacel Pharmaceuticals Inc Earnings CallSee More Headlines Receive CYCCP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cyclacel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Ex-Dividend for 2/1 Dividend1/19/2024Dividend Payable2/01/2024Today3/28/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:CYCCP CUSIPN/A CIK1130166 Webwww.cyclacel.com Phone+1-908-5177330FaxN/AEmployees12Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Spiro George Rombotis (Age 62)Pres, CEO & Exec. Director Comp: $772.64kMr. Paul McBarron (Age 60)Exec. VP of Fin., CFO, COO, Sec. & Exec. Director Comp: $391.91kDr. Mark H. Kirschbaum M.D. (Age 60)Sr. VP & Chief Medical Officer Comp: $354.73kMs. Gill Christie (Age 64)Director of HR Dr. Robert Westwood Ph.D. (Age 77)Head of Preclinical Devel. and VP of Chemistry & Preclinical Devel. Key Competitors180 Life SciencesNASDAQ:ATNFW60 Degrees PharmaceuticalsNASDAQ:SXTPWAlpha Tau MedicalNASDAQ:DRTSWApollomicsNASDAQ:APLMWArtelo BiosciencesNASDAQ:ARTLWView All Competitors CYCCP Stock Analysis - Frequently Asked Questions How often does Cyclacel Pharmaceuticals pay dividends? What is the dividend yield for Cyclacel Pharmaceuticals? Cyclacel Pharmaceuticals declared a quarterly dividend on Friday, January 12th. Shareholders of record on Monday, January 22nd will be paid a dividend of $0.15 per share on Thursday, February 1st. This represents a $0.60 annualized dividend and a yield of 3.36%. The ex-dividend date of this dividend is Friday, January 19th. Read our dividend analysis for CYCCP. Is Cyclacel Pharmaceuticals a good dividend stock? Cyclacel Pharmaceuticals (NASDAQ:CYCCP) pays an annual dividend of $0.60 per share and currently has a dividend yield of 0.12%. Read our dividend analysis for CYCCP. This page (NASDAQ:CYCCP) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingFed launches fourth dollar overhaulStansberry Research“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyclacel Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.